Literature DB >> 26903389

The Role of APOE in the Occurrence of Frontotemporal Dementia in Amyotrophic Lateral Sclerosis.

Adriano Chiò1, Maura Brunetti2, Marco Barberis2, Barbara Iazzolino2, Anna Montuschi2, Antonio Ilardi2, Stefania Cammarosano2, Antonio Canosa2, Cristina Moglia2, Andrea Calvo3.   

Abstract

IMPORTANCE: Amyotrophic lateral sclerosis (ALS) is a heterogeneous disease with a wide spectrum of involvement of cognitive functions. The mechanisms of this heterogeneity are still largely unknown, but genetic variants may account for this variability.
OBJECTIVE: To assess the influence of the apolipoprotein E (APOE) and C9ORF72 genotypes on cognitive impairment in a population-based series of Italian patients with ALS. DESIGN, SETTING, AND PARTICIPANTS: All 504 patients with ALS living in Piemonte, Italy, diagnosed between January 1, 2009, and December 31, 2013, and identified through the Piemonte and Valle d'Aosta register for ALS, were eligible to participate in the study. Controls were 223 age- and sex-matched individuals identified through the patients' general practitioners. Data analysis was performed from June 1 to December 31, 2014. MAIN OUTCOMES AND MEASURES: The presence of APOE and C9ORF72 genotypes was assessed. Patients were cognitively classified as having ALS with normal cognition, ALS with frontotemporal dementia (FTD), ALS with executive or nonexecutive impairment, and ALS with behavioral impairment.
RESULTS: Of the 504 patients with incident ALS, 357 (70.8%) were included in the study; 154 were women, 203 were men, they had a mean (SD) age at onset of 64.8 (10.2) years, and 37 of them carried a C9ORF72 repeat expansion. Cognitive testing revealed that 184 patients (51.5%) had ALS with normal cognition, 51 (14.3%) had ALS with FTD, 103 (28.9%) had ALS with executive or nonexecutive impairment, and 19 (5.3%) had ALS with behavioral impairment. Distribution of APOE haplotypes did not significantly differ between patients and controls or among patients with different levels of cognitive impairment. According to multivariate logistic regression, the presence of C9ORF72 repeat expansions was the strongest determinant of FTD (odds ratio, 13.08; 95% CI, 4.75-36.02; P < .001); however, the presence of an APOE ε2 allele significantly increased the risk of FTD (odds ratio, 2.61; 95% CI, 1.14-6.10; P = .03). Presence of an APOE ε4 allele was ineffectual. CONCLUSIONS AND RELEVANCE: C9ORF72 repeat expansions have a primary role in increasing the risk of cognitive impairment in patients with ALS; the APOE ε2 allele, to a lesser extent, also increases the risk of FTD. These study findings highlight the importance of considering the genetic background of patients with ALS when analyzing the putative effect of genetic modifiers.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26903389     DOI: 10.1001/jamaneurol.2015.4773

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  13 in total

1.  To Dement or Not to Dement, That Is the Question.

Authors:  Bryan J Traynor; Yevgeniya A Abramzon
Journal:  JAMA Neurol       Date:  2016-04       Impact factor: 18.302

2.  Comorbidity of dementia with amyotrophic lateral sclerosis (ALS): insights from a large multicenter Italian cohort.

Authors:  Francesca Trojsi; Mattia Siciliano; Cinzia Femiano; Gabriella Santangelo; Christian Lunetta; Andrea Calvo; Cristina Moglia; Kalliopi Marinou; Nicola Ticozzi; Gianluca Drago Ferrante; Carlo Scialò; Gianni Sorarù; Amelia Conte; Yuri M Falzone; Rosanna Tortelli; Massimo Russo; Valeria Ada Sansone; Adriano Chiò; Gabriele Mora; Barbara Poletti; Paolo Volanti; Claudia Caponnetto; Giorgia Querin; Mario Sabatelli; Nilo Riva; Giancarlo Logroscino; Sonia Messina; Antonio Fasano; Maria Rosaria Monsurrò; Gioacchino Tedeschi; Jessica Mandrioli
Journal:  J Neurol       Date:  2017-09-15       Impact factor: 4.849

Review 3.  Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria.

Authors:  Michael J Strong; Sharon Abrahams; Laura H Goldstein; Susan Woolley; Paula Mclaughlin; Julie Snowden; Eneida Mioshi; Angie Roberts-South; Michael Benatar; Tibor HortobáGyi; Jeffrey Rosenfeld; Vincenzo Silani; Paul G Ince; Martin R Turner
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2017-01-05       Impact factor: 4.092

4.  Updated meta-analysis of the role of APOE ε2/ε3/ε4 alleles in frontotemporal lobar degeneration.

Authors:  Wen-Hua Su; Zhi-Hong Shi; Shu-Ling Liu; Xiao-Dan Wang; Shuai Liu; Yong Ji
Journal:  Oncotarget       Date:  2017-07-04

5.  Impact of Apolipoprotein E gene polymorphism during normal and pathological conditions of the brain across the lifespan.

Authors:  Diego Iacono; Gloria C Feltis
Journal:  Aging (Albany NY)       Date:  2019-01-24       Impact factor: 5.682

Review 6.  Therapeutic approaches targeting Apolipoprotein E function in Alzheimer's disease.

Authors:  Tosha Williams; David R Borchelt; Paramita Chakrabarty
Journal:  Mol Neurodegener       Date:  2020-01-31       Impact factor: 18.879

7.  Association of APOE e2 genotype with Alzheimer's and non-Alzheimer's neurodegenerative pathologies.

Authors:  Terry E Goldberg; Edward D Huey; D P Devanand
Journal:  Nat Commun       Date:  2020-09-18       Impact factor: 14.919

8.  Frontotemporal Dementia in Amyotrophic Lateral Sclerosis: From Rarity to Reality?

Authors:  Marco Orsini; Ana Carolina Andorinho de Freitas Ferreira; Osvaldo J M Nascimento; Jano Alves de Souza; Thaís Nascimento Magalhães; Anna Carolina Damm de Assis; Larissa Kozow Westin; Bruno Pessoa; Acary Bulle Oliveira; Rossano Fiorelli; Marcos R G de Freitas; Juliana Bittencourt; Stenio Fiorelli; Maria Fernanda Freitas Ferreira Moreira; Pedro Ribeiro
Journal:  Neurol Int       Date:  2016-06-29

9.  Cognitive decline in amyotrophic lateral sclerosis: Neuropathological substrate and genetic determinants.

Authors:  Sergi Borrego-Écija; Janina Turon-Sans; Teresa Ximelis; Iban Aldecoa; Laura Molina-Porcel; Mónica Povedano; Miguel Angel Rubio; Josep Gámez; Antonio Cano; Martí Paré-Curell; Lorena Bajo; Javier Sotoca; Jordi Clarimón; Mircea Balasa; Anna Antonell; Albert Lladó; Raquel Sánchez-Valle; Ricard Rojas-García; Ellen Gelpi
Journal:  Brain Pathol       Date:  2021-02-12       Impact factor: 6.508

10.  TDP-43 mediates SREBF2-regulated gene expression required for oligodendrocyte myelination.

Authors:  Wan Yun Ho; Jer-Cherng Chang; Kenneth Lim; Amaury Cazenave-Gassiot; Aivi T Nguyen; Juat Chin Foo; Sneha Muralidharan; Ashley Viera-Ortiz; Sarah J M Ong; Jin Hui Hor; Ira Agrawal; Shawn Hoon; Olubankole Aladesuyi Arogundade; Maria J Rodriguez; Su Min Lim; Seung Hyun Kim; John Ravits; Shi-Yan Ng; Markus R Wenk; Edward B Lee; Greg Tucker-Kellogg; Shuo-Chien Ling
Journal:  J Cell Biol       Date:  2021-08-04       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.